Latest News and Press Releases

MELBOURNE, Australia, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to...

MELBOURNE, Australia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce the initiation of several studies designed to add to the...

MELBOURNE, Australia, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van...

MELBOURNE, Australia, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Following the US$1.7B proposed takeover of Tobira by Allergan, three more Licensing Mergers & Acquisitions (LM&A) transactions over...

FARMINGTON, Conn., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Immuron Limited: The latest travel forecast released this week by AAA, projects that 103 million Americans will travel during the December 23,...

MELBOURNE, Australia, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company, Immuron Limited (ASX:IMC), is pleased to announce today that it filed its Registration Statement on Form...

MELBOURNE, Australia, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession...

FARMINGTON, Conn., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Immuron Limited: According to AAA research released this week, 48.7 million Americans are expected to travel within the U.S. this...

MELBOURNE, Australia, July 25, 2016 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) announces the availability of its presentation from RedChip’s Small Stocks, Big Money Investor...

MELBOURNE, Australia, July 20, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced it has formed a strategic...